Hormel Foods' Former CEO Returns To Lead Company
The stock of Hormel Foods (HRL) is up on reports that the company’s former Chief Executive Officer (CEO) Jeffrey Ettinger is returning to the helm on an interim basis. Ettinger has reportedly agreed to return to the CEO role for a period of 15 months beginning on July 14 of this year.Hormel Foods has been a going concern since 1891 and today makes well-known products such as Skippy peanut butter and Planters nuts, as well as bacon and various meats. Ettinger, 66, served as Hormel’s CEO from 2005 to 2016. He now replaces current Hormel CEO and President James Snee, age 57, who announced his retirement in January of this year. The CEO transition comes after the company lowered its annual profit forecast as it struggles with supply chain issues and weakening consumer demand.Snee will serve as a special advisor to the company until October 26, and Hormel expects him to stay on as a consultant for another 18 months after that, the company said in a statement.Hormel Foods said it plans to name a permanent CEO in October 2026.The company has also appointed John Ghingo, executive vice-president of the company’s retail business, as its new president, also effective July 14.HRL stock has declined 37% over the last five years to trade at $30.41 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


